Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1

Context Cholangiocarcinoma with highly heterogeneous, aggressive, and multidrug resistance has a poor prognosis. Although babaodan (BBD) combined with cisplatin improved non-small cell lung cancer efficacy, its impact on overcoming resistance in cholangiocarcinoma remains unexplored.Objective This s...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiong Li, Xiangjun Ma, Faying Xu, Yuanliang Yan, Weiqing Chen
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Pharmaceutical Biology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/13880209.2024.2331060
Tags: Add Tag
No Tags, Be the first to tag this record!